Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

The Commercial Impact of REMS Relief: Nplate/Promacta Sales Spike After Risk Management Changes

This article was originally published in RPM Report

Executive Summary

Nplate and Promacta aren’t the most important products sold by Amgen and GSK. But they are among the fastest growing in 2012—thanks to a decision by FDA to relax post-market controls at the end of 2011. The change underscores the case for a different approach to REMS in oncology, and may point the way forward for broader use of the new tools in a less intrusive way.

Advertisement

Related Content

FDAAA Impact Analysis (Year 4): The REMS Retreat Continues - For Now
Carving REMS Out of Oncology? FDA, ASCO Plan Follow-Up Workshop
REMS 2.0: FDA Refining New Drug Safety Tools
The Rebirth of A Niche Product: Three Silver Linings on the ESA REMS
Living With REMS: The New Regulatory Model Meets Commercial Reality

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS080945

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel